89bio, Inc. - Common Stock (NQ:ETNB)

14.84 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

December 07, 2023

From 89bio, Inc.

Via GlobeNewswire

Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 07, 2023

U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following...

Via Benzinga

Topics Stocks

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

December 06, 2023

From 89bio, Inc.

Via GlobeNewswire

Analyst Ratings for 89bio ↗

November 28, 2023

Via Benzinga

Analyst Expectations for 89bio's Future ↗

October 11, 2023

Via Benzinga

89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease ↗

December 04, 2023

89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in

Via Benzinga

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

December 04, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details ↗

November 27, 2023

89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with

Via Benzinga

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

November 27, 2023

From 89bio, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for 89bio ↗

September 22, 2023

Via Benzinga

Analyst Ratings for 89bio ↗

August 10, 2023

Via Benzinga

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

November 21, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

November 12, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

November 08, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

October 17, 2023

From 89bio, Inc.

Via GlobeNewswire

Why Shares of 89bio Plummeted on Tuesday ↗

October 10, 2023

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

Via The Motley Fool

Akero Therapeutics' Disappointing NASH Data Drags Its Rival ↗

October 10, 2023

Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 10, 2023

Via Benzinga

Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 10, 2023

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.

Via Benzinga

Why Akero Therapeutics Stock Is Crashing Today ↗

October 10, 2023

Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).

Via The Motley Fool

PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday ↗

October 10, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Topics Stocks

US Stocks Gain; PepsiCo Posts Upbeat Earnings ↗

October 10, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%...

Via Benzinga

Topics Stocks

Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio ↗

October 10, 2023

Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 09, 2023

Via Benzinga

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

September 21, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio to Participate in the 2023 Cantor Global Healthcare Conference

September 20, 2023

From 89bio, Inc.

Via GlobeNewswire

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 05, 2023

From 89bio, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.